Logo image of ARTL

ARTELO BIOSCIENCES INC (ARTL) Stock Price, Quote, News and Overview

NASDAQ:ARTL - Nasdaq - US04301G5080 - Common Stock - Currency: USD

1.015  +0 (+0.5%)

ARTL Quote, Performance and Key Statistics

ARTELO BIOSCIENCES INC

NASDAQ:ARTL (5/2/2025, 9:38:24 AM)

1.015

+0 (+0.5%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High1.59
52 Week Low0.82
Market Cap3.33M
Shares3.28M
Float3.25M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-08 2025-05-08
IPO10-13 2015-10-13


ARTL short term performance overview.The bars show the price performance of ARTL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10

ARTL long term performance overview.The bars show the price performance of ARTL in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of ARTL is 1.015 USD. In the past month the price increased by 14.77%. In the past year, price decreased by -25.19%.

ARTELO BIOSCIENCES INC / ARTL Daily stock chart

ARTL Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 59.99 782.57B
JNJ JOHNSON & JOHNSON 15.51 375.56B
NVO NOVO-NORDISK A/S-SPONS ADR 20.05 307.89B
NVS NOVARTIS AG-SPONSORED ADR 13.79 226.38B
AZN ASTRAZENECA PLC-SPONS ADR 19.31 222.67B
MRK MERCK & CO. INC. 10.8 211.70B
PFE PFIZER INC 7.54 137.18B
SNY SANOFI-ADR 14.38 135.92B
BMY BRISTOL-MYERS SQUIBB CO 6.79 101.41B
GSK GSK PLC-SPON ADR 7.15 79.76B
ZTS ZOETIS INC 26.92 71.08B
HLN HALEON PLC-ADR 22.07 48.80B

About ARTL

Company Profile

ARTL logo image Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquartered in Solana Beach, California and currently employs 6 full-time employees. The company went IPO on 2015-10-13. The firm is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

Company Info

ARTELO BIOSCIENCES INC

505 Lomas Santa Fe, Suite 160

Solana Beach CALIFORNIA 92037 US

CEO: Gregory D. Gorgas

Employees: 5

Company Website: https://artelobio.com/

Investor Relations: https://ir.artelobio.com/

Phone: 18589257049

ARTELO BIOSCIENCES INC / ARTL FAQ

What is the stock price of ARTELO BIOSCIENCES INC today?

The current stock price of ARTL is 1.015 USD. The price increased by 0.5% in the last trading session.


What is the ticker symbol for ARTELO BIOSCIENCES INC stock?

The exchange symbol of ARTELO BIOSCIENCES INC is ARTL and it is listed on the Nasdaq exchange.


On which exchange is ARTL stock listed?

ARTL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ARTELO BIOSCIENCES INC stock?

9 analysts have analysed ARTL and the average price target is 5.61 USD. This implies a price increase of 452.71% is expected in the next year compared to the current price of 1.015. Check the ARTELO BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ARTELO BIOSCIENCES INC worth?

ARTELO BIOSCIENCES INC (ARTL) has a market capitalization of 3.33M USD. This makes ARTL a Nano Cap stock.


How many employees does ARTELO BIOSCIENCES INC have?

ARTELO BIOSCIENCES INC (ARTL) currently has 5 employees.


What are the support and resistance levels for ARTELO BIOSCIENCES INC (ARTL) stock?

ARTELO BIOSCIENCES INC (ARTL) has a support level at 0.97 and a resistance level at 1.05. Check the full technical report for a detailed analysis of ARTL support and resistance levels.


Should I buy ARTELO BIOSCIENCES INC (ARTL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ARTELO BIOSCIENCES INC (ARTL) stock pay dividends?

ARTL does not pay a dividend.


When does ARTELO BIOSCIENCES INC (ARTL) report earnings?

ARTELO BIOSCIENCES INC (ARTL) will report earnings on 2025-05-08.


What is the Price/Earnings (PE) ratio of ARTELO BIOSCIENCES INC (ARTL)?

ARTELO BIOSCIENCES INC (ARTL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.05).


What is the Short Interest ratio of ARTELO BIOSCIENCES INC (ARTL) stock?

The outstanding short interest for ARTELO BIOSCIENCES INC (ARTL) is 26.92% of its float. Check the ownership tab for more information on the ARTL short interest.


ARTL Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to ARTL. When comparing the yearly performance of all stocks, ARTL is a bad performer in the overall market: 77.5% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ARTL Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ARTL. ARTL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ARTL Financial Highlights

Over the last trailing twelve months ARTL reported a non-GAAP Earnings per Share(EPS) of -3.05. The EPS increased by 4.39% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -209.15%
ROE -343.93%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-12.5%
Sales Q2Q%N/A
EPS 1Y (TTM)4.39%
Revenue 1Y (TTM)N/A

ARTL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to ARTL. The Buy consensus is the average rating of analysts ratings from 9 analysts.


Ownership
Inst Owners1.15%
Ins Owners0.83%
Short Float %26.92%
Short Ratio1.75
Analysts
Analysts82.22
Price Target5.61 (452.71%)
EPS Next Y61.21%
Revenue Next YearN/A